📈 SIGNAL

MRNA Stock Sentiment Today: BULLISH

Moderna Inc · HEALTHCARE · AI news analysis · updated 2026-09-01

Bullish
60%
Neutral
20%
Bearish
20%

Moderna received a significant analyst upgrade from Argus Research to Buy with a $180 price target, driving bullish momentum despite near-term stock weakness from a debt offering announcement. The company benefits from Big Pharma sector strength and expanding mRNA pipeline opportunities, though regulatory headwinds from potential Trump administration drug pricing curbs present near-term uncertainty.

Price
$140.34
1M Change
+156.0%
Market Cap
55.09B
Analyst Target
$107
Market backdrop: Signal Sentiment Index 68 · bullish zone · this week's full recap →
~100-day price trend

Key themes driving MRNA sentiment

Analyst upgrades and positive price target revisionsmRNA platform expansion and variant vaccine updatesSector-wide Big Pharma recovery on strong Q2 earningsRegulatory risk from potential drug pricing controls

Recent headlines behind the verdict

This is a cached daily reading.
Get a live MRNA analysis — fresh headlines, full fundamentals, analyst targets — in 30 seconds. Free.
Run a live analysis →
More tickers: ZMMDBAMZNXOMNFLXACNQCOMDISBLKRTXSBUXVRTX

Sentiment reflects AI analysis of published news headlines as of 2026-09-01 and can change at any time. For informational purposes only · Not financial advice · signalsentiment.com